Clinical trials: Male Pattern Baldness
Androgenetic Alopecia
the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending
The study is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and PK of KX-826 following topical multiple ascending dose administration.
- Trial name
- NCT04502901
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Alopecia, Androgenetic
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- NCT05244980
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
Androgenetic Alopecia, Female Pattern Baldness
Clinical Study of Probiotic Treatment for Androgenetic Alopecia
The primary objective of the study is to assess the efficacy of DA-001 as an oral supplement for treatment of female pattern hair loss.
- Trial name
- NCT06484881
- Testing
- Daniel Alain Probiotic Treatment for Androgenetic Alopecia, Topical minoxidil 5%
- Sponsor
- Applied Biology, Inc.
Androgenetic Alopecia
24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness
The purpose of this study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia
- Trial name
- NCT01686295
- Testing
- iRestore Hair Rejuvenation System
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Freedom Laser Therapy, Inc.
Androgenetic Alopecia
Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia
The purpose of this study is to evaluate the safety and efficacy in relation to dosing in the administration of Hair Stimulating Complex (HSC) in healthy men.
- Trial name
- HSC Phase I/II (NCT01501617)
- Testing
- Hair Stimulating Complex (HSC), Dulbecco's Modified Eagle Medium, DMEM
- Where
- Philippines
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Histogen
Androgenetic Alopecia
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.
- Trial name
- NCT02279823
- Testing
- CB-03-01 solution, Minoxidil Solution 5%
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- Intrepid Therapeutics, Inc.
Androgenetic Alopecia, Female Pattern Baldness
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
The primary objective of the study is to assess the safety and efficacy of DA-005 and DA-002 as a treatment for hair loss (androgenetic alopecia).
- Conditions
- Androgenetic Alopecia, Female Pattern Baldness, Male Pattern Baldness
- Trial name
- NCT06501924
- Testing
- DA-005, Topical minoxidil 5%, DA-002
- Volunteers
- 516 people
- Sponsor
- Applied Biology, Inc.
Alopecia, Androgenetic
STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia
The primary objective of this study is to evaluate the safety and feasibility of the Celution and Puregraft Systems in the processing and preparation of an autologous fat graft enriched with adipose-derived regenerative cells…
- Trial name
- STYLE (NCT02503852)
- Testing
- Puregraft System, Celution System, Kerastem Therapy
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- Kerastem Technologies, LLC
Androgenetic Alopecia
A Study to Evaluate the Efficacy and Safety of AD-208
The purpose of this study is to evaluate the efficacy and safety of AD-208.
- Trial name
- NCT04825561
- Testing
- AD-208, AD-2081
- Where
- South Korea
- Volunteers
- 139 people
- Sponsor
- Addpharma Inc.
Androgenetic Alopecia
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
- Trial name
- NCT06916793
- Testing
- CKD-843 dose#1, CKD-843 dose#2, Dutasteride Capsules
- Where
- South Korea
- Volunteers
- 288 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Androgenetic Alopecia
Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration
The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following…
- Trial name
- NCT04984707
- Testing
- KX0826
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Androgenetic Alopecia
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV…
- Trial name
- NCT00471510
- Testing
- tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Neosil, Inc.
Alopecia, Androgenetic
A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, fixed volume, randomized, double-blind, vehicle-controlled, parallel group, dose escalation comparison study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- AGA (NCT04913519)
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
Androgenetic Alopecia, Hair Loss
Treatment of Androgenic Alopecia in Males
The purpose of this study is to evaluate the change in terminal hair count at 16 and 26 weeks compared to baseline measurements.
- Conditions
- Androgenetic Alopecia, Hair Loss, Male Pattern Baldness
- Trial name
- NCT00947219
- Testing
- HairMax LaserComb, Control device
- Where
- 3 sites in United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)
The purpose of the study is to evaluate the ability of injections of Ji Gami(TM) or Ji Gami(TM) DO in combination with minoxidil to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451125
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety…
- Trial name
- NCT07076706
- Testing
- minoxidil + finasteride
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Beijing Dayspring Pharmaceutical Technology Co., Ltd
Male Pattern Baldness, Female Pattern Baldness
Low Level Light Therapy (LLLT) for Hair Growth
A total of 62 participants will receive red light (660 nm) to the scalp through a specially designed light therapy device integrated into a conventional hat.
- Trial name
- NCT03938948
- Testing
- low-level laser/light therapy
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Awareable Technologies Inc
AGA
A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects
1. To evaluate the safety and tolerability of CU-40101 liniment as a single and multiple topical application in adult male androgenic alopecia subjects； 2.
- Trial name
- NCT05380427
- Testing
- CU-40101
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Androgenetic Alopecia, Androgenetic Alopecia (AGA)
Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia.
This study is a Phase 3 clinical trial designed to evaluate the efficacy and safety of N1087 compared with placebo in adult men with androgenetic alopecia (male pattern hair loss).
- Trial name
- MINORA-MEN (NCT07529977)
- Testing
- Minoxidil oral solution
- Volunteers
- 372 people
- Sponsor
- Eurofarma Laboratorios S.A.
Telogen Effluvium, Female Pattern Hair Loss
Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for Hair Shedding Reduction and Hair Re-Growth
- Conditions
- Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia, Male Pattern Baldness
- Trial name
- NCT06648850
- Testing
- DA-001, Phenylephrine, DA-001 Topical + DA-005 Oral (HIF-1α supplement)
- Volunteers
- 1,120 people
- Sponsor
- Applied Biology, Inc.